Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA457432
Max Phase: Preclinical
Molecular Formula: C14H25NO11
Molecular Weight: 383.35
Molecule Type: Small molecule
Associated Items:
ID: ALA457432
Max Phase: Preclinical
Molecular Formula: C14H25NO11
Molecular Weight: 383.35
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(=O)N[C@@H]1[C@@H](O)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@@H](CO)O[C@H]1O
Standard InChI: InChI=1S/C14H25NO11/c1-4(18)15-7-9(20)12(6(3-17)24-13(7)23)26-14-11(22)10(21)8(19)5(2-16)25-14/h5-14,16-17,19-23H,2-3H2,1H3,(H,15,18)/t5-,6-,7-,8+,9-,10+,11-,12-,13-,14+/m1/s1
Standard InChI Key: KFEUJDWYNGMDBV-LODBTCKLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: Yes | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 383.35 | Molecular Weight (Monoisotopic): 383.1428 | AlogP: -5.25 | #Rotatable Bonds: 5 |
Polar Surface Area: 198.40 | Molecular Species: NEUTRAL | HBA: 11 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 12 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 11.50 | CX Basic pKa: | CX LogP: -4.99 | CX LogD: -4.99 |
Aromatic Rings: 0 | Heavy Atoms: 26 | QED Weighted: 0.23 | Np Likeness Score: 2.03 |
1. Dumas DP, Ichikawa Y, Wong C, Lowe JB, Nair RP. (1991) Enzymatic synthesis of sialyl Lex and derivatives based on a recombinant fucosyltransferase, 1 (8): [10.1016/S0960-894X(00)80270-X] |
2. Dumas DP, Ichikawa Y, Wong C, Lowe JB, Nair RP. (1991) Enzymatic synthesis of sialyl Lex and derivatives based on a recombinant fucosyltransferase, 1 (8): [10.1016/S0960-894X(00)80270-X] |
3. Jain RK, Locke RD, Chandrasekaran E, Matta KL. (1992) Synthesis of 2-O-substituted -D-Gal-(14)--D-GlcNAc-1-0-Bn as specific acceptors for -L-(13) fucosyltransferases, 2 (1): [10.1016/S0960-894X(00)80656-3] |
4. Delaine T, Cumpstey I, Ingrassia L, Le Mercier M, Okechukwu P, Leffler H, Kiss R, Nilsson UJ.. (2008) Galectin-inhibitory thiodigalactoside ester derivatives have antimigratory effects in cultured lung and prostate cancer cells., 51 (24): [PMID:19053747] [10.1021/jm801077j] |
5. Masaka R, Ogata M, Misawa Y, Yano M, Hashimoto C, Murata T, Kawagishi H, Usui T.. (2010) Molecular design of N-linked tetravalent glycosides bearing N-acetylglucosamine, N,N'-diacetylchitobiose and N-acetyllactosamine: Analysis of cross-linking activities with WGA and ECA lectins., 18 (2): [PMID:20056550] [10.1016/j.bmc.2009.12.006] |
Source(1):